Metabolically Armed CD19 CAR-T cells is named as a drug or biological intervention in 3 clinical trials in our China trial register, 3 of which are recruiting. Lead sponsors include Zhejiang University (2) and He Huang (1). Registered phase: Phase EARLY_PHASE1. Conditions studied include Systemic Lupus Erythematosus; Diffuse Large B-cell Lymphoma; Non-hodgkin Lymphoma,B Cell.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06120166 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research (ClinicalTrials.gov ↗) Diffuse Large B-cell Lymphoma |
Phase EARLY_PHASE1 | Recruiting |
| NCT06711146 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research (ClinicalTrials.gov ↗) Systemic Lupus Erythematosus |
Phase EARLY_PHASE1 | Recruiting |
| NCT06716164 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research (ClinicalTrials.gov ↗) Non-hodgkin Lymphoma,B Cell |
Phase EARLY_PHASE1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Systemic Lupus Erythematosus | 1 |
| Diffuse Large B-cell Lymphoma | 1 |
| Non-hodgkin Lymphoma,B Cell | 1 |
| Lead sponsor | Trials |
|---|---|
| Zhejiang University | 2 |
| He Huang | 1 |
| Register | Metabolically Armed CD19 CAR-T cells trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Metabolically Armed CD19 CAR-T cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Metabolically Armed CD19 CAR-T cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.